Search Bar & Filters
Found 10 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of the drug rilvegostomig compared with pembrolizumab as a first-line treatment for patients with metastatic non-small cell lung cancer mNSCLC whose tumors have high levels of PD-L1. This Phase III, randomized, double-blind, global study focuses on patients with mNSCLC who meet specific genetic and health criteria to understand how these treatments perform in this group. Participants receive either rilvegostomig or pembrolizumab, both given intravenously on the first day of each 21-day treatment cycle. The study has two groups one receiving rilvegostomig and the other pembrolizumab, with treatments continuing as part of their first-line cancer care. The trial monitors these treatments over several years to assess long-term outcomes. During the study, participants will have regular assessments including scans to measure tumor response, evaluations of physical function, quality of life questionnaires, and tests to monitor drug levels and immune responses. The main outcomes tracked are overall survival and progression-free survival over approximately five years. Safety and patient-reported symptoms are also closely monitored throughout the study period.
Actively Recruiting
Researchers are evaluating saruparib AZD5305 added to standard radiation therapy RT and androgen deprivation therapy ADT compared to placebo in men with high-risk and very high-risk localized or locally advanced prostate cancer who have a BRCA1 or BRCA2 gene mutation. This Phase III randomized, double-blind, placebo-controlled study aims to assess whether saruparib improves metastasis-free survival in this specific group of patients. Participants will be divided into two groups Cohort A includes men with newly diagnosed high-risk prostate cancer or high-risk biochemical recurrence after radical prostatectomy, receiving saruparib or placebo with ADT Cohort B includes men with very high-risk prostate cancer receiving saruparib or placebo combined with ADT plus abiraterone and prednisoloneprednisone. Saruparib and placebo are given orally, alongside standard treatments, and participants will receive the treatment and follow-up according to their assigned cohort. During the study, participants will undergo scans including CT or MRI, bone scans, and PSMA-PET to monitor disease status. Researchers will track survival outcomes, metastasis-free survival up to about 93 months, and overall survival up to 11 years. Blood samples will measure drug concentrations, and safety will be monitored through adverse event reporting. Participants will be followed until the study ends, with ongoing assessments to evaluate treatment effects and safety.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of ZL-1310 compared to the Investigators Choice Therapy in participants with relapsed small cell lung cancer SCLC. This phase 3 study aims to understand how well ZL-1310, a DLL3 antibody-drug conjugate, works against SCLC that has returned after initial treatment, with a focus on response rates and overall survival. Participants will receive either ZL-1310 as a single drug or Investigators Choice Therapy, which includes options like Topotecan or Amrubicin. The study is randomized and open-label, meaning participants are assigned to one of these treatments without masking. Treatment effects will be monitored over up to 30 months, with evaluations conducted regularly throughout this period. During the trial, participants will undergo tumor biopsies or provide archived tumor tissue samples at screening. They will be assessed for measurable disease and monitored for response using standard criteria RECIST v1.1, as well as quality of life measures. Safety will be tracked by recording treatment-related side effects and adverse events. The study includes comprehensive evaluations of survival, response duration, progression-free survival, and central nervous system responses, with participation lasting up to nearly three years.
Actively Recruiting
This research aims to evaluate the effectiveness of AZD5335 compared to standard treatments in women with high-grade, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. The study focuses on whether AZD5335 improves progression-free survival PFS among participants with either high or low levels of folate receptor alpha FR. Approximately 1100 adult women will be enrolled and divided into two groups based on their FR levels. Participants will be randomized within each group to receive either AZD5335 or the relevant standard treatment. Those with high FR levels will receive AZD5335 or mirvetuximab soravtansine, while those with low FR levels will receive AZD5335 or a chemotherapy agent chosen by the investigator, including paclitaxel, pegylated liposomal doxorubicin, or topotecan. Treatments are given intravenously, and participants will continue treatment until disease progression or other reasons for stopping. During the study, participants will undergo regular tumor assessments to monitor disease status. Researchers will follow all participants over time to evaluate overall survival. Safety and efficacy data will be reviewed periodically by an independent committee. The primary outcome is progression-free survival, measured for up to about five years. The study completion is expected by late 2029.
Actively Recruiting
Researchers are evaluating zongertinib, alone and combined with other treatments, for adults aged 18 and older who have various types of HER2-positive cancers that have spread and cannot be removed by surgery. This study focuses on patients whose tumors show HER2 abnormalities and who have not responded to prior treatments. The goal is to find a suitable dose of zongertinib that patients can tolerate well and to see if the treatment can shrink tumors. Participants receive treatment in cycles and are assigned to different groups. In Part 1, groups receive increasing doses of zongertinib combined with one of several other drugs, including trastuzumab deruxtecan, trastuzumab emtansine, trastuzumab with capecitabine, zanidatamab, or mFOLFOX6 chemotherapy. In Part 2, participants are randomly assigned to groups receiving different doses of zongertinib alone or with these treatments. Some groups also participate in an extension phase. The study is open-label and conducted at multiple centers. During the study, participants visit the study site regularly for tumor assessments using CT or MRI scans, health monitoring, and reporting of any side effects. Researchers track tumor size changes, dose-limiting toxicities within 21 days, and objective responses up to 50 months. Patient-reported outcomes and other safety and pharmacokinetic measurements are also collected. Participants remain under medical observation throughout the study, which may last several years.
Actively Recruiting
Researchers are evaluating standard neoadjuvant treatment options for patients aged 70 years or older with high-risk stage II and stage III rectal cancer in a multicentre, open-label, randomized clinical trial called SHAPERS. The study compares conventional neoadjuvant therapy with total neoadjuvant therapy TNT to understand their safety and effectiveness for this older patient group. Participants are randomly assigned to one of two groups. The conventional treatment group receives either short course radiotherapy followed by surgery or watch & wait, with optional adjuvant chemotherapy, or long course chemoradiotherapy followed by surgery or watch & wait, also with optional adjuvant chemotherapy. The TNT group receives one of several treatment regimens decided by the investigator before randomization, including combinations of short course radiotherapy, oxaliplatin-based chemotherapy lasting up to 18 weeks, and chemoradiotherapy, followed by surgery or watch & wait. During the study, participants undergo treatments as assigned and are monitored for outcomes including overall survival, progression-free survival, peripheral sensory neuropathy, and severe toxicities over 3 years after randomization. Researchers will gather information about treatment effects, side effects, and patient survival to compare the two approaches. The study includes follow-up assessments to track these outcomes and participant safety throughout the trial duration.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of two drug combinations for treating patients with hormone receptor-positive, HER2-negative advanced breast cancer that has a PIK3CA mutation. This phase 3, open-label, global study compares RLY-2608 zovegalisib plus fulvestrant against capivasertib plus fulvestrant following disease recurrence or progression after prior treatment with a CDK46 inhibitor. The study focuses on patients whose cancer has advanced locally or metastasized and have specific genetic mutations influencing treatment response. Participants will receive one of two treatment combinations zovegalisib taken orally twice daily together with fulvestrant given by intramuscular injection on specified days in a 28-day cycle, or capivasertib taken orally twice daily on an intermittent weekly schedule combined with the same fulvestrant regimen. Treatment cycles repeat every 28 days. The study will monitor and compare these combinations over several months to assess outcomes. Throughout the study, participants will undergo regular assessments including imaging scans to measure cancer progression, blood tests to monitor drug levels, and questionnaires to evaluate quality of life. Researchers will track progression-free survival, overall survival, response rates, duration of response, clinical benefit, and safety profiles. The study duration may extend up to approximately 77 months, with ongoing monitoring of health status and adverse events to gather comprehensive data on treatment impact.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of datopotamab deruxtecan Dato-DXd compared with docetaxel in patients who have advanced or metastatic non-squamous non-small cell lung cancer NSCLC that is positive for trophoblast cell surface protein 2 TROP2 and lacks actionable genomic alterations. This phase III study is randomized, open-label, and includes two groups to compare these treatments in participants who have previously received therapy. Participants receive either Dato-DXd or docetaxel through intravenous infusions every three weeks, with each treatment given on the first day of a 21-day cycle. The study also evaluates the performance of an investigational diagnostic device that measures TROP2 levels. This two-arm study runs until disease progression or other discontinuation criteria are met. During the study, participants undergo regular assessments including imaging scans to measure tumor size, laboratory tests to check organ function, and questionnaires related to lung cancer symptoms, physical function, and quality of life. Researchers will monitor progression-free survival and overall survival over approximately 2.5 to 3.5 years, along with secondary outcomes such as response rates and duration of response. Safety and tolerability are also evaluated throughout the trial.
Actively Recruiting
Researchers are studying metastatic pancreatic ductal adenocarcinoma PDA in adults who have not been previously treated for this condition. The trial evaluates the effect of adding SBP-101, a small molecule polyamine metabolic inhibitor, to the standard chemotherapy regimen of gemcitabine and nab-paclitaxel. This randomized, double-blind, placebo-controlled, multicenter study aims to assess overall survival and other important outcomes in about 600 patients. Participants will receive either SBP-101 combined with nab-paclitaxel and gemcitabine or a placebo with the same chemotherapy drugs. The treatments are given as injections, and the study includes two groups one experimental arm receiving SBP-101 plus chemotherapy and one control arm receiving placebo plus chemotherapy. The safety and effectiveness of treatments will be monitored throughout the trial by an independent committee. During the study, patients will be followed for overall survival up to 100 weeks or until death. Researchers will also measure progression-free survival, responses seen on scans, and quality of life. Assessments include imaging with CT or MRI, blood tests, and monitoring of side effects. Participants must consent to the study and meet specific health criteria, and safety will be closely observed throughout the trial period.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of Rina-S as a monotherapy treatment for advanced gastrointestinal GI cancers in participants who have progressed after standard treatments. This Phase 2, open-label study involves multiple cohorts across various countries and focuses on participants with metastatic or unresectable GI cancer who meet specific health criteria. Participants will receive Rina-S through intravenous administration at doses specified for different cohorts. All participants will receive the active drug no placebo is involved. The treatment cycles last 21 days, with 1 to 5 visits per cycle. Treatment may continue as long as the cancer remains stable or improves and the study is ongoing. The average treatment period is expected to be about 12 months, within an overall average study duration of 22 months that includes data collection before and after treatment. During the study, participants will have regular visits for safety monitoring and assessments, including blood tests, heart activity recordings, and imaging such as X-rays. Researchers will measure outcomes like tumor response, disease control, progression-free survival, and treatment-related adverse events. Pharmacokinetics of Rina-S will also be studied. Participants health will be closely observed throughout the study duration, which may last up to 22 months.